Expert Council Resolution on Pathogenetically Substantiated Approach to Management and Rehabilitation of Children with Acute Intestinal Infections and Functional Gastrointestinal Disorders with the Inclusion of Probiotics and Intestinal Motility Modulators in Treatment Protocols

On March 14, 2026, the Council of Experts was held to address the issue of functional gastrointestinal disorders (FGIDs) in children, including those following acute intestinal infections (AIIs). It was noted that AIIs remain a significant medical and social problem in pediatrics, carrying risks of dehydration, toxic shock, organ damage, and the development of long-term post-infectious complications that impair quality of life. The experts confirmed the key role of baseline therapy for AIIs (oral/parenteral rehydration and diet therapy) and discussed the addition of the probiotic strain Lactobacillus rhamnosus GG (LGG) to standard protocols as an evidence-based approach to reducing the duration and severity of diarrhea and restoring gut microbiota, that may decrease the risk of subsequent FGIDs. In cases of already established FGIDs in children with a predominance of pain and spastic syndromes in the absence of organic pathology, the Council recommended thorough diagnostic evaluation and the use of trimebutine, a universal gastrointestinal motility regulator, including its novel pediatric gel formulation (Dinobutin), which provides analgesic, antispasmodic, and motility-normalizing effects and is potentially associated with higher adherence in children. It was noted that the combined use of LGG and trimebutine (for example, Normobact L and Dinobutin) may yield a more sustained clinical effect in children with FGIDs. The meeting concluded with a proposed management algorithm for patients with AIIs and post-infectious FGIDs, which could significantly improve patient outcomes and quality of life.

1. Gorelov A, Usenko D. Rotavirus infection in children. Voprosy sovremennoi pediatrii — Current Pediatrics. 2008;7(6):78–84 (In Russ).

2. Usenko DV, Gorelova EA. Acute intestinal infections of viral etiology in children: prospects for diagnosis and therapy. Meditsinskiy sovet = Medical Council. 2017;(9):86–92. (In Russ).

3. Senina NS, Vlasova AV, Chekhova VO, Simonova VG. Modern approaches to therapeutic nutrition in acute intestinal infections in children. Meždunarodnyj studenčeskij naučnyj vestnik. 2024;(6). (In Russ).

4. Sergevnin VI. Modern Trends in Long-Term Dynamics of the Acute Intestinal Infectios Incidence of Bacterial and Viral Etiology. Epidemiology and Vaccinal Prevention. 2020;19(4):14–19. (In Russ). doi: https://doi.org/10.31631/2073-3046-2020-19-4-1419]

5. Meskina ER. Treatment of acute infectious diarrhea in children: current trends and open issues. Russian Journal of Woman and Child Health. 2025;8(3):263– 270. (In Russ). doi: https://doi.org/10.32364/2618-8430-2025-83-12]

6. Mina S, Daher S, Jamal Elddin S, et al. Post-infectious irritable bowel syndrome in a paediatric population: first data in a Middle Eastern country. BMC Pediatr. 2025;25(1):531. doi: https://doi.org/10.1186/s12887-025-05872-6

7. Sadeghi A, Biglari M, Nasseri Moghaddam S. Post-infectious irritable bowel syndrome: A narrative review. Middle East J Dig Dis. 2019;11(2):69–75. doi: https://doi.org/10.15171/mejdd.2019.130

8. Khavkin AI, Nalyotov AV, Naletova PI. Prospects for pharmacotherapy of functional gastrointestinal disorders in children: The role of advanced oral formulations. Meditsinskiy sovet = Medical Council. 2026;(1):133–138. (In Russ). doi: https://doi.org/10.21518/ms2026-017]

9. Belmer SV, Volynets GV, Gorelov АV, et al. Funktsional’nye rasstroistva organov pishchevareniya u detei. Guidelines of Society of Pediatric Gastroenterologists, Hepatologists and Nutritionists. 02/04/2020. Moscow; 2021. 64 p. (In Russ). doi: https://doi.org/10.21508/KR-2021] Доступно по: https://disk.yandex.ru/i/se92riDa2PKd1A. Ссылка активна на 05.06.2026.

10. Ivashkin VT, Shelygin YuA, Baranov AA, et al. Sindrom razdrazhennogo kishechnika: deti, vzroslye: Clinical guidelines. Moscow; 2024. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/preview-cr/892_1. Ссылка активна на 05.06.2026.

11. Indrio F, Neu J, Pettoello-Mantovani M, et al. Development of the Gastrointestinal Tract in Newborns as a Challenge for an Appropriate Nutrition: A Narrative Review. Nutrients. 2022;14(7):1405. doi: https://doi.org/10.3390/nu14071405

12. Chanpong A, Borrelli O, Thapar N. The Potential Role of Microorganisms on Enteric Nervous System Development and Disease. Biomolecules. 2023;13(3):447. doi: https://doi.org/10.3390/biom13030447

13. Henderickx JGE, Zwittink RD, Renes IB, et al. Maturation of the preterm gastrointestinal tract can be defined by host and microbial markers for digestion and barrier defense. Sci Rep. 2021;11(1):12808. doi: https://doi.org/10.1038/s41598-021-92222-y

14. Pantazi AC, Mihai CM, Lupu A, et al. Gut Microbiota Profile and Functional Gastrointestinal Disorders in Infants: A Longitudinal Study. Nutrients. 2025;17(4):701. doi: https://doi.org/10.3390/nu17040701

15. Ihekweazu FD, Versalovic J. Development of the Pediatric Gut Microbiome: Impact on Health and Disease. Am J Med Sci. 2018;356(5):413–423. doi: https://doi.org/10.1016/j.amjms.2018.08.005

16. Saeed NK, Al-Beltagi M, Bediwy AS, et al. Gut microbiota in various childhood disorders: Implication and indications. World J Gastroenterol. 2022;28(18):1875–1901. doi: https://doi.org/10.3748/wjg.v28.i18.1875

17. Heiss CN, Olofsson LE. The role of the gut microbiota in development, function and disorders of the central nervous system and the enteric nervous system. J Neuroendocrinol. 2019;31(5):e12684. doi: https://doi.org/10.1111/jne.12684

18. Guarino A, Ashkenazi S, Gendrel D, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr. 2014;59(1):132–152. doi: https://doi.org/10.1097/MPG.0000000000000375

19. Guarino A, Aguilar J, Berkley J, et al. Acute Gastroenteritis in Children of the World: What Needs to Be Done? J Pediatr Gastroenterol Nutr. 2020;70(5):694–701. doi: https://doi.org/10.1097/MPG.0000000000002669

20. NamazovaBaranova LS, Fedoseenko MV, Vishneva EA, et al. Vaccination against rotavirus infection: 10-year global experience of successful use. Voprosy sovremennoi pediatrii — Current Pediatrics. 2017;16(4):273–285. (In Russ). doi: https://doi.org/10.15690/vsp.v16i4.1773]

21. Lobzin YuV, Uskov AN, Bekhtereva MK, et al. Rotavirusnyi gastroehnterit u detei: Clinical guidelines. Moscow; 2023. 45 p. (In Russ). Доступно по: https://cr.minzdrav.gov.ru/view-cr/755_1. Ссылка активна на 05.06.2026.

22. Insoft RM, Sanderson IR, Walker WA. Development of immune function in the intestine and its role in neonatal diseases. Pediatr Clin North Am. 1996;43(2):551–571. doi: https://doi.org/10.1016/S0031-3955(05)70420-x

23. Furlano RI, Walker WA. Immaturity of gastrointestinal host defense in newborns and gastrointestinal disease states. Adv Pediatr. 1998;45:201–222

24. Kotloff KL, Nataro JP, Blackwelder WC, et al. Burden and aetiology of diarrhoeal disease in infants and young children in developing countries (the Global Enteric Multicenter Study, GEMS): a prospective, case-controlstudy. Lancet. 2013;382(9888):209–222. doi: https://doi.org/10.1016/S0140-6736(13)60844-2

25. Vandenplas Y, Salvatore S, Vieira M, et al. Probiotics in infectious diarrhoea in children: are they indicated? Eur J Pediatr. 2007;166(12):1211–1218. doi: https://doi.org/10.1007/s00431-007-0497-9

26. Capozza M, Laforgia N, Rizzo V, et al. Probiotics and Functional Gastrointestinal Disorders in Pediatric Age: A Narrative Review. Front Pediatr. 2022;10:805466. doi: https://doi.org/10.3389/fped.2022.805466

27. Collinson S, Deans A, Padua-Zamora A, et al. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2020;12(12):CD003048. doi: https://doi.org/10.1002/14651858.CD003048.pub4

28. Huang R, Xing HY, Liu HJ, et al. Efficacy of probiotics in the treatment of acute diarrhea in children: a systematic review and meta-analysis of clinical trials. Transl Pediatr. 2021;10(12):3248– 3260. doi: https://doi.org/10.21037/tp-21-511

29. Gorelov AV, Kanner ЕV, Maximov ML, et al. Lactobacillus rhamnosus GG: clinical aspects of the use from the perspective of evidence-based medicine. Meditsinskiy sovet = Medical Council. 2018;(17):66–73. (In Russ). doi: https://doi.org/10.21518/2079-701X-2018-17-66-73

30. Guandalini S, Pensabene L, Zikri MA, et al. Lactobacillus GG administered in oral rehydration solution to children with acute diarrhea: a multicenter European trial. J Pediatr Gastroenterol Nutr. 2000;30(1):54–60. doi: https://doi.org/10.1097/00005176-200001000-00018

31. Szajewska H, Berni Canani R, Domellöf M, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023;76(2):232–247. doi: https://doi.org/10.1097/MPG.0000000000003633

32. Hojsak I, Szajewska H, Canani RB, et al. Probiotics for the Prevention of Nosocomial Diarrhea in Children. J Pediatr Gastroenterol Nutr. 2018;66(1):3–9. doi: https://doi.org/10.1097/MPG.0000000000001637

33. Scalabrin D, Harris C, Johnston W, et al. Long-term safety assessment in children who received hydrolyzed protein formulas with Lactobacillus rhamnosus GG: a 5-year follow-up. Eur J Pediatr. 2017;176(2):217–224. doi: https://doi.org/10.1007/s00431-016-2825-4

34. Guarner F, Sanders ME, Szajewska H, et al. World Gastroenterology Organisation Global Guidelines: Probiotics and Prebiotics. J Clin Gastroenterol. 2024;58(6):533–553. doi: https://doi.org/10.1097/MCG.0000000000002002

35. Package leaflet for the dietary supplement Normobact L. СГР KZ.16.01.95.003.E.000017.01.19 dated 01/09/2019. (In Russ).

36. Razuvaeva YuYu, Kolomatskaya VV, Ledneva VS. Analysis of the prevalence of functional gastrointestinal diseases. In: VI International Scientific and Practical Conference of Young Scientists and Students “Issues of Modern Medical Science and Health Care”. 2021. pp. 385–388 (In Russ).

37. Patient information leaflet for Dinobutin gel for oral administration with strawberry flavor. ЛП-№(000622)-(РГ-RU) dated 27/11/2025. (In Russ).

38. ИМП Дротаверин. ЛП-№(010906)-(РГ-RU) от 10.07.2025. [IMU Drotaverine. ЛП-№(010906)-(РГ-RU) dated 10/07/2025. (In Russ).

39. Package leaflet for Buscopan tablets for oral administration. П N014393/01 dated 15/08/2008. (In Russ).

40. Package leaflet for the drug Domperidone oral suspension. ЛП-№(009203)-(РГ-RU) dated 11/03/2025. (In Russ).

41. Листок-вкладыш Метаклопрамид таблетки для приема внутрь. ЛП-№(002257)-(РГ-RU) от 27.04.2023. [Package leaflet Metaclopramide tablets for oral administration. ЛП-№ (002257)-(РГ-RU) dated 27/04/2023. (In Russ).

42. Package leaflet Simethicone. ЛП-№(006519)-(РГ-RU) dated 09/08/2024. (In Russ).

43. ИМП Лоперамид капсулы. ЛП-№(001609)-(РГ-RU) от 27.12.2022. [IMU Loperamide capsules. ЛП-№(001609)-(РГ-RU) dated 27/12/2022. (In Russ).

44. ИМТ Лактулоза сироп. ЛП-№(001433)-(РГ-RU) от 18.11.2022. [IMU Lactulose syrup. ЛП-№(001433)-(РГ-RU) dated 18/11/2022. (In Russ).

45. Package leaflet for Smecta powder for suspension. ЛП-№(004897)-(РГ-RU) dated 18/03/2024. (In Russ).

46. ИМТ Панкреатин. ЛП-006509 от 15.10.2020. [IMU Pancreatin. ЛП-006509 dated 15/10/2020. (In Russ).

47. Ivashkin VT, Gorelov AV, Abdulganieva DI, et al. Methodological Guidelines of the Scientific Community for Human Microbiome Research (CHMR) and the Russian Gastroenterology Association (RGA) on the Use of Probiotics, Prebiotics, Synbiotics, Metabiotics and Functional Foods Enriched with Them for the Treatment and Prevention of Gastrointestinal Diseases in Adults and Children. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(4):113–136. (In Russ). doi: https://doi.org/10.22416/1382-4376-2024117-312

48. Baryshnikova NV. The effectiveness of trimebutin in the treatment of functional diseases of the gastrointestinal tract. Polyklinika. 2024;(5):13–18. (In Russ).

49. Karabulut GS, Beşer OF, Erginöz E, et al. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment. J Neurogastroenterol Motil. 2013;19(1):90–93. doi: https://doi.org/10.5056/jnm.2013.19.1.90

50. Akopyan AN, Belmer SV, Vykhristyuk ОF, et al. Gastroesophageal reflux and gastrointestinal-motility disorders. Doktor.Ru. 2014;(11):45–49. (In Russ).

51. Shadrin OG, Platonova YeM, Garynycheva TA. New opportunities for treatment of combined functional gastrointestinal disorders in children. Child’s Health. 2012;(5):21–25. (In Russ).

52. Belmer SV, Gasilina TV, Kovalenko AA, Karpina LM. Modern ways of correction of functional disorders of the digestive organs in children. Voprosy detskoi dietologii = Pediatric Nutrition. 2011;9(2):10–14. (In Russ).

53. Gorelov AV. Ostrye kishechnye infektsii u detei: karmannyi, spravochnik. Moscow: GEOTAR-Media; 2026. 96 p. (In Russ).

54. Guimarães M, Statelova M, Holm R, Reppas C, et al. Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products — a PEARRL review. J Pharm Pharmacol. 2019;71(4):603–642. doi: https://doi.org/10.1111/jphp.12955

55. Tipikina MYu, Korniyenko YeA. New aspects of the mechanisms of development and treatment of irritable bowel syndrome. Pediatrician. 2013;4(3):29–35. (In Russ). doi: https://doi.org/10.17816/PED4329-35

56. Yu QX, Wang DD, Dong PJ, Zheng LH. Probiotics Combined With Trimebutine for the Treatment of Irritable Bowel Syndrome Patients: A Systematic Review and Meta-Analysis. J Gastroenterol Hepatol. 2025;40(3):677–691. doi: https://doi.org/10.1111/jgh.16858

57. Gawrońska A, Dziechciarz P, Horvath A, Szajewska H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children. Aliment Pharmacol Ther. 2007;25(2):177–184. doi: https://doi.org/10.1111/j.13652036.2006.03175.x

58. Glotova AP, Mironova OM, Zaitseva LYu. The structure of dysbiotic disorders in children who have had salmonellosis, and how to correct them. Modern problems of science and education. 2019;(5). (In Russ).

59. Dietoterapiya ostrykh kishechnykh infektsii u detei. Bekhtereva MK, Skripchenko NV, eds. St. Petersburg; 2014. 36 p. (In Russ).

60. Federal Law dated November 21, 2011 No. 323-ФЗ “Ob osnovakh okhrany zdorov’ya grazhdan v Rossiiskoi Federatsii” (with amendments and additions). (In Russ). Доступно по: http://www.consultant.ru/document/cons_doc_LAW_121895. Ссылка активна на 05.06.2026.

61. Federal Law dated December 30, 2021 No. 482-ФЗ “O vnesenii izmenenii v Federal’nyi zakon “Ob osnovakh okhrany zdorov’ya grazhdan v Rossiiskoi Federatsii”. (In Russ). Доступно по: http://www.consultant.ru/document/cons_doc_LAW_405472. Ссылка активна на 05.06.2026.

62. Order of the Government of the Russian Federation dated May 16, 2022 No. 1180-р. (In Russ). Доступно по: http://publication.pravo.gov.ru/Document/View/0001202205170014. Ссылка активна на 05.06.2026.